Based on these trials, in March 2019, dapagliflozin was approved by the EMA as an add-on treatment to insulin in adults with T1D and BMI ≥ 27 kg/m2 who could not achieve adequate glycaemic control with insulin alone [6]. This evidence concerns the gene INS and type 1 diabetes mellitus.